CREON has a well-characterized safety profile

Safety data collected from clinical trials of CREON in various patient populations.

Adverse reactions reported in at least 1 patients (≥4%) with EPI in the chronic Pancreatitis or Pancreatectomy Pivotal trials1
CREON vs Placebo CREON n=25 (%) Placebo n=29 (%)
Hyperglycemia 2 (8%) 2 (7%)
Hypoglycemia 1 (4%) 1 (3%)
Abdominal pain 1 (4%) 1 (3%)
Abnormal feces 1 (4%) 0 (0%)
Flatulence 1 (4%) 0 (0%)
Frequent bowel movements 1 (4%) 0 (0%)
Nasopharyngitis 1 (4%) 0 (0%)
Adverse Reactions Occurring in at Least 2 Patients ( ≥4%) in Cystic Fibrosis
CREON vs Placebo CREON n=49 (%) Placebo n=47 (%)
Vomiting 3 (6%) 1 (2%)
Dizziness 2 (4%) 1 (2%)
Cough 2 (4%) 0 (0%)

An open-label, single-arm study assessed the short-term safety and tolerability of CREON in 18 infants and children with EPI due to CF1

  • The primary objective of this study was to observe the safety and tolerability profile of CREON compared with the standard PERT therapy in children under 71
  • This study included patients with a confirmed diagnosis of EPI due to CF aged 4 months to 6 years1
  • Adverse reactions that occurred in patients during treatment with CREON in this open-label study were vomiting, irritability, and decreased appetite, each occurring in 6% of patients1

Find out how to determine an appropriate CREON dose, set treatment expectations with patients, and more.

See treatment initiation reminders

In clinical trials, CREON demonstrated efficacy across multiple indications and age groups.1

Review efficacy data

CF = cystic fibrosis; EPI = exocrine pancreatic insufficiency; PERT = pancreatic enzyme replacement therapy.